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AbstractWe report here on a case of Ewing sarcoma (ES) occurring in a child with neurofi-
bromatosis type 1. The sarcoma had an EWSR1-ERG translocation as well as loss of the re-
maining wild-type allele of NF1. Loss of theNF1 wild-type allele in the tumor suggests that
activation of the Ras pathway contributed to its evolution. Review of available public data
suggests that secondary mutations in the Ras pathway are found in ∼3% of ESs. This case
suggests that Ras pathway activationmay play a role in tumor progression in a subset of ESs.
[Supplemental material is available for this article.]
INTRODUCTION
Ewing sarcoma (ES) is a highly malignant tumor that originates in the bone and/or soft tissue.
Although it is a rare cancer with an incidence reported of anywhere from one to three people
diagnosed per million in a year (Ries et al. 1999; Esiashvili et al. 2008; Potratz et al. 2012), it
is the second most common primary malignancy of the bone following osteosarcoma
(Esiashvili et al. 2008). The median age of diagnosis is 14–15 yr of age, although 20%–
30% of cases are diagnosed in the first decade of life and cases continue to be diagnosed
beyond the second decade with decreasing frequency (Bernstein et al. 2006; Potratz et al.
2012; Rochefort et al. 2017). Age is also a prognostic factor in this disease with individuals
under the age of 15 having a better outcome than those 15 yr and older (PDQ Pediatric
Treatment Editorial Board 2019).
Molecularly, ES is characterized by the presence of the EWSR1 gene fusions with one of
several genes from the E26 transformation-specific (ETS) family of transcription factors, such
as FLI1, ERG, ETV1, ETV4, and FEV (Delattre et al. 1994; Burchill 2008; Grünewald et al.
2018; Nakano and Takahashi 2018). ESWR1 is a member of the ten–eleven translocation
(TET) family (Tan andManley 2009) and in rare cases FUS, another member of the TET family
(Tan andManley 2009), can substitute for EWSR1 (Gamberi et al. 2011). Additionally, there is
an emerging new molecular category—Ewing-like tumor—that is morphologically similar to
ES but has EWSR1 fusions involving non-ETS genes (Renzi et al. 2019) as well as fusions with
genes other than ETS or TET family members (e.g., CIC-DUX4, BCOR-CCNB3) (Cohen-
Gogo et al. 2014; Specht et al. 2014). Of the EWSR1-ETS fusions in ES, the EWSR1-FLI1
fusion (t(11;22)(q24;q12)) is the most commonly detected and found in 85% of cases. The
EWSR1-ERG fusion (t(21;22)(q22;q12)) is the next most common pairing, detected in any-
where from 5% to 10% of cases (Gamberi et al. 2011).
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To date, there are no clinically recognized hereditary cancer syndromes that predispose
individuals to ES, although it has been a topic of investigation. One group described an in-
creased incidence of neuroectodermal tumors and stomach cancer in relatives of patients
with ES, although no causative genetic factor was identified (Novakovic et al. 1994). A large
case-control study that sequenced 1162 sarcoma probands, including 134 of the Ewing sub-
type, reported a significant association between germlinemutations in FANCgenes and sar-
comas characterized by somatic translocations (Ballinger et al. 2016). Other reported
associations of germline mutations with ES include mutations in DNA repair pathway genes
such as TP53, PMS2, and others, as well as known hereditary cancer syndrome genes such as
RET, PTCH2, ATM, and others (Zhang et al. 2015; Brohl et al. 2017). ES has also rarely been
described as a second malignancy in patients with heritable retinoblastoma (Cope et al.
2001). Importantly, although these associations exist, there is little evidence demonstrating
that these germline alterations played a pathogenic role in the development of ES.
Neurofibromatosis type 1 (NF-1) is an autosomal dominant hereditary cancer syndrome
caused by germline loss-of-function mutations in the NF1 gene, which encodes a RAS-
GTPase-activating protein that functions as a negative regulator of Ras proteins (Cichowski
and Jacks 2001). It affects one in 2500–3500 individuals worldwide irrespective of sex or eth-
nic background and imparts a higher risk of developing tumors (Hirbe and Gutmann 2014).
NF-1 patients develop a variety of tumors by inactivation of the remaining wild-type allele of
NF1. Almost all individuals with NF-1 will develop pigmentary skin lesions, such as café au
lait macules, axillary or inguinal freckling, and/or Lisch nodules. A subset of individuals
also develops skeletal abnormalities, neurologic difficulties, cardiovascular abnormalities,
and/or tumors. These tumors can bemalignant or benign, with benign neurofibromas occur-
ring in 99% of individuals (Ferner 2010). The lifetime risk of cancer developing in patients
with NF-1 is estimated to be ∼7% (Hirbe and Gutmann 2014). Optic pathway gliomas are
the most common central nervous system (CNS) tumor seen in NF-1 patients (Lewis et al.
1984), but other CNS tumors also occur (Nix et al. 2019). Additionally, non-CNS solid tumors,
such as pheochromocytoma (Walther et al. 1999) and breast cancer (Sharif et al. 2007), as
well as hematologic malignancies have been reported (Seminog and Goldacre 2013;
Hirbe and Gutmann 2014).
A wide variety of sarcomas are associated with NF-1. Malignant peripheral nerve sheath
tumors commonly occur arising from a plexiform or nodular neurofibroma. Less commonly, a
wide variety of other sarcomas may occur including gastrointestinal stromal tumor (GIST)
(Hurley et al. 2018), rhabdomysarcoma (Ferrari et al. 2007), osteosarcoma, and leiomyosar-
coma (Afsa̧r et al. 2013; Kim et al. 2017). We found one report of an NF-1 patient with ES
(Chowdhry et al. 2009) and another NF-1 patient with a Ewing-like sarcoma driven by a
CIC-DUX4 fusion (Tardío et al. 2015).
Here we describe a 3-yr-old child with NF-1, who was diagnosed with EWSR1-ERG
fusion–positive ES that also harbored a somatic mutation of NF1 in addition to a germline
nonsense mutation of NF1. The second hit on NF1 suggests that biallelic inactivation of
NF1 provided a growth advantage to the tumor cells and highlights the potential role of
Ras pathway mutations as secondary events in ES.
RESULTS
A previously healthy, 3-yr-old girl presented with a 3-wk history of back pain and an 8-wk his-
tory of tiptoe walking. Her mother reported a clinical diagnosis of NF-1 made in Mexico; she
has overt multiple neurofibromas and café au lait spots on her face and arms. The patient had
not been tested for NF1 at the time of presentation. However, on physical examination she
appeared to have a clinical diagnosis of NF-1: more than six café au lait spots and axillary
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freckling without overt neurofibromas (National Institutes of Health 1988). She appeared un-
comfortable and was febrile with an occasional cough on initial presentation. Auscultation
was notable for decreased breath sounds over the left lung. Her neurological examination
showed adequatemovement of the lower extremities as well as muscle tone, but she refused
to stand up and walk.
A chest radiograph demonstrated two densities in the left and right paraspinal region
centered around T7, measuring 3.8×2.7 cm and 5.8×4.4×4.5 cm, respectively. A CT of
the chest demonstrated a posterior mediastinal tumor of the mid-thoracic spine with bony
destruction of T7 and tumor encroachment of the spinal cord, extending into the spinal canal
from T6 to T8 (Fig. 1A–C).
A biopsy of the mass showed a highly cellular, high-grade neoplasm composed of sheets
of plump spindle cells in short fascicles alternating with fibrovascular septa (Fig. 2A). The tu-
mor cells contained scant cytoplasm, large round nuclei with vesicular chromatin and prom-
inent nucleoli. Focal perivascular areas contained smaller round cells with conspicuous
nuclear molding (Fig. 2B). Mitotic activity was brisk (more than 20 mitotic figures/10 high-
power fields). Immunohistochemistry revealed the cells to be positive for synaptophysin in
a perivascular distribution (Fig. 2C), whereas SOX10 was positive in scattered smaller spindle
cells dispersed throughout the spindle cell areas (Fig. 2D). In addition, tumor cells were pos-
itive for vimentin, CD99 (Fig. 2F), and neuron-specific enolase (NSE) with retained BAF47 ex-
pression (not shown). Conversely, no staining for keratins, CD45, muscle-specific actin,
smooth muscle actin, desmin, epithelial membrane antigen, chromogranin, or glial fibrillary
acid protein (GFAP) was identified. H3K27Me3 showed a mosaic pattern of expression (Fig.
2E). Although the histology of the tumor was consistent with ES, FISH analysis of the tumor
specimen showed no structural rearrangements associated with ES, although gains of
A B C
D E F
Figure 1. Diagnostic (A–C ) and postinduction chemotherapy (D–F ) MRI. (A) Coronal, (B) sagittal, and (C ) axial
views demonstrating paraspinal tumor with the displacement of the aorta and esophagus anteriorly and en-
croachment of the left and right hilar and bronchi as well as the left atrium and pulmonary veins. The estimated
tumor volume was calculated at 720 mm3. (D) Coronal, (E) sagittal, and (F ) axial views demonstrating good re-
sponse to induction chemotherapy. Estimated tumor volume is 120 mm3, which represents an 84% reduction
of baseline tumor size.
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12q13.1 (FOXO1), 18q11.2 (SS18), and 22q12 (EWSR1) were observed (Supplemental
Table 2). Further diagnostic classification was therefore sought by utilizing a targeted
sequencing panel specifically designed to evaluate selected exons and introns for cancer-
relevant genes and a subset of known fusions (Kline et al. 2017). DNA was extracted from
tumor and blood. Panel testing revealed a truncating mutation of NF1 (p.K2396∗) in the tu-
mor and an inactivating NF1mutation that was also present in the blood sample (p.Y2285∗)
(Table 1; Supplemental Fig. 1), likely resulting in biallelic inactivation ofNF1. In addition, the
tumor harbored an EWSR1-ERG fusion, confirming the diagnosis of ES (Table 1; Fig. 3). No
other pathogenic variants were detected in the submitted tumor specimen.
Pending sequencing results, Ewing therapywith concurrent radiation therapy was started
after surgical resection of the tumor using an interval-compression chemotherapy consisting
of vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etopo-
side given the tumor histologically appeared to be consistent with ES and because of the
rapidly evolving cord compression. The patient tolerated chemotherapy well and after
A B
C D
E F
Figure 2. (A) The tumor was composed of short fascicles of plump spindle cells. (B) The tumor cells had scant
cytoplasm, large nuclei with vesicular chromati, and brisk mitotic activity (arrows). Clusters of rounder cells with
nuclear molding were observed around vessels (arrowhead). (C ) Synaptophysin was expressed in a perivascu-
lar pattern in the round cells. (D) SOX10 showed staining in scattered smaller cells. (E) H3K27Me3 immunohis-
tochemistry showed a patchy (so-called “mosaic”) pattern of H3K27Me expression. The dot-like staining in
most cells represents inactivated X chromosome(s) (Schaefer et al. 2016). Multiple such signals in some nuclei
may represent X-chromosome duplication. (F ) CD99 expression. (A) Original magnification, 100×; (B–E) orig-
inal magnification, 200×; (F ) original magnification, 40×.
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Table 1. Variant table
Gene Chr
HGVS DNA
reference
HGVS protein
reference
Variant
type
Predicted
effect
dbSNP/dbVar
ID
Genotype or
allele frequency ClinVar ID
Blood sample
NF1 17 c.6855C>A p.Y2285∗ Nonsense Pathogenic rs772295894 Heterozygous 185082
Tumor tissue
NF1 17 c.7186A>T p. K2396∗ Nonsense Pathogenic Not reported 37% allele
frequency
Not reported
NF1 c.6855C>A p.Y2285∗ Nonsense Pathogenic rs772295894 57% allele
frequency
185082
EWSR1,
ERG
22, 21 t(21;22)(q22;q12) EWSR1-ERG Fusion Pathogenic Not applicable Not available Not
reported
Figure 3. Integrated Genome Viewer snapshot of the chimeric read pairs mapping to intron 7 of ERG on
Chromosome 21 (genomic position indicated by red arrow at ideogram at top) and intron 8 of EWSR1 and
on Chromosome 22 (genomic position indicated by red arrow at ideogram at top). The blue boxes at the bot-
tom indicate the position of exons 6, 7, and 8 of ERG and 8 and 9 of EWSR1. The sequencing assay tiles over
introns 5–13 of EWSR1 and all its exons. Only exons of ERG are captured and are not shown in the left panel
because of the height of the chimeric read pile over ERG intron 7. Reads are colored by insert size. The gray
reads over ESWR1 at the bottom of the right panel show the unrearranged background reads over the cap-
tured region of ESWR1.
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two cycles of chemotherapy the tiptoewalking resolved. Evaluation of response at the end of
six cycles of induction chemotherapy showed dramatic improvement in the intraspinal tu-
mor. Measurements of the right and left paraspinous thoracic tumor showed a >80%
decrease in volume compared to baseline (Fig. 1D–F). The patient completed treatment
and is currently doing well 3 mo after completion of therapy.
DISCUSSION
Ewing sarcoma in patients with NF-1 has been reported only once in the literature (Chowdhry
et al. 2009), although in that report there was no characterization of the type of ES fusion or
NF1 mutations. In the case reported here, an EWSR1-ERG fusion was detected by a next-
generation sequencing (NGS) assay but not by FISH. False-negative results using dual
break-apart probes for the detection of the EWSR1-ERG fusion can occur because of the
complex nature of this rearrangement (Chen et al. 2016).
Mechanistically, EWSR1-ETS fusions exert their oncogenic affect by driving dramatic
changes in the transcriptome of cells harboring the fusion (Erkizan et al. 2010). Receptor ty-
rosine kinases (RTKs) have been shown to have higher transcript expression levels in ES tu-
mors (Potratz et al. 2016), and as the Ras pathway is a major effector of downstream signaling
for RTKs, it may represent an important mediator of the oncogenic effects of EWSR1 fusions.
IGFR1 is a well-established RTK that has been shown to be essential in this capacity (Gaspar
et al. 2012). In support of this, inhibition of the Ras pathway through MEK1/2 inhibitors has
been shown to suppress malignant phenotypes in ES cell lines (Silvany et al. 2000; Benini
et al. 2004). Additionally, two independent studies reported down-regulation of SPRY1
and miRNA let-7, both negative regulators of RAS, in ES cell lines resulting in Ras pathway
activation (Hameiri-Grossman et al. 2015; Cidre-Aranaz et al. 2017). It is interesting to spec-
ulate that as Ras is a main converging point for downstream signaling of activated RTKs
up-regulated in ES, the acquisition of mutations or implementation of other molecular mech-
anisms that can result in Ras pathway activation may be advantageous to ES cells. NF1 is one
such target as it is a negative regulator of the Ras pathway, where it catalyzes the hydrolysis of
Ras-bound guanosine triphosphate (GTP) to guanine diphosphate (GDP) and keeps Ras in
the active state (Cichowski and Jacks 2001).
The patient presented here had two NF1 mutations. The germline NF1 p.Y2285∗
(c.6855C>A) found in the patient described here is a known pathogenic variant associated
with NF-1 (Table 1; ClinVar ID 185082). The somatic nonsense mutation p.K2396∗
seen in this patient has been reported in a single sample of a grade IV astrocytoma
(COSM5766195). It is not present in ClinVar or LOVDbut is predicted to result in protein trun-
cation and classified as a PVS1 according to ACMGguidelines (Richards et al. 2015). The two
nonsense mutations affected different exons so that they could not be phased. However, we
also observed a large deletion of Chromosome 17, where NF1 resides in the tumor (Fig. 4).
One possible explanation for this observation is that the tumor is polyploid and duplicate
copies of the wild-type NF1 gene were removed by two independent events—the tumor-
specific p.K2396∗ mutation and loss of a chromosome. Although polyploidy was originally
suggested by the EWSR1 FISH results showing copy-number increase of the locus
(Supplemental Table 2), chromosome analysis (Supplemental Fig. 2) subsequently revealed
a normal female complement with no abnormal clones detected. An alternative explanation
is the presence of heterogeneity in the tumor. The second hit somatic mutation in NF1 was
present at an allele frequency of 37%, which could suggest a subclonal nature to this muta-
tion. Although not definitive, the two nonsense mutations in NF1 in conjunction with the
Chromosome 17 deletion encompassing NF1 favor a model of biallelic inactivation and re-
duces the likelihood that NF1 inactivation is happening by chance in this tumor; biallelic
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inactivation of NF1 suggests that there was a selective advantage to losing the wild-type al-
lele and that NF1 is contributing to sarcomagenesis.
Mutations in Ras pathway genes have only infrequently been reported in ES (Shukla et al.
2012; Zhang et al. 2016). Querying the GENIE cBioPortal database (v5.0) confirmed the pau-
city of Ras pathway mutations in ES, with only four cases of 143 ES patients in whose tumors
mutated Ras pathway genes were detected (AACR Project GENIE Consortium 2017).
This case highlights several important aspects of the evaluation of solid tumors and the
roleofNGSanalysis in their evaluation. First, it demonstrates thatNGScan sometimes identify
pathogenic fusions events not detected by standard methods. In this particular case, NGS
testing was used to confirm the diagnosis of ES. This highlights the potential utility of NGS,
although it should be noted that access to this technology continues to be limited, especially
in middle- and low-income countries. Other immunohistochemistry-based tests may be use-
ful for confirming ES in patients (Baldauf et al. 2018). Second, it demonstrates the utility of
Figure 4. Genome-wide copy-number changes. The y-axis shows the log2 ratio of normalized ratio of copy-
number changes in the tumor to a reference genomewith 0 corresponding to no copy-number change. The x-
axis shows the genome from Chromosome 1 to Chromosome Y. The upper panel shows the copy number
across the genome; the lower panel shows the variant allele frequency.
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NGS analysis in tumors from patients with inherited cancer predispositions, as it can evaluate
the role of the inherited predisposition in the pathogenesis of specific cancer under
study. In the case reported here, NGS clearly demonstrated a likely role for the inherited
predisposition because the tumor acquired a second hit in the same gene. Last, this
case underscores the underappreciated role of the Ras pathway in the pathogenesis and pro-
gression of ES.
METHODS
NGS Testing
GenomicDNAwas extracted from tumor tissue that had beenmacrodissected from formalin-
fixed, paraffin-embedded blocks and blood. Capture-based next-generation DNA sequenc-
ing was performed as previously described at the UCSF Clinical Cancer Genomics
Laboratory, using an assay that targets all coding exons of 479 cancer-related genes,
TERT promoter, select introns, and upstream regulatory regions of 47 genes
(Supplemental Table 1) to enable detection of structural variants including gene fusions
and DNA segments at regular intervals along each chromosome to enable genome-wide
copy-number and zygosity analysis, with a total sequencing footprint of 2.8 Mb.
Sequencing libraries were prepared from genomic DNA, and target enrichment was per-
formed by hybrid capture using a custom oligonucleotide library (Roche NimbleGen).
Sequencing was performed on an Illumina HiSeq 2500. Tumors are sequenced to an average
unique depth coverage of approximately >500×. Duplicate sequencing reads were removed
computationally to allow for accurate allele frequency determination and copy-number call-
ing. The analysis was based on the human reference sequence (NCBI build 37) using the fol-
lowing software packages: BWA 0.7.13, Samtools 1.1 (using htslib 1.1), Picard tools 1.97
(1504), GATK Appistry v2015.1.1-3.4.46-0-ga8e1d99, CNVkit 0.7.2, Pindel 0.2.5b8, SATK
Appistry v2015.1.1-1-gea45d62, ANNOVAR v2016Feb01, FreeBayes 0.9.20, and Delly
0.7.2.13-20 Single-nucleotide variants, insertions/deletions, and structural variants were visu-
alizedandverifiedusing the IntegratedGenomeViewer.Genome-widecopy-numberanalysis
based on on-target and off-target reads was performed by CNVkit (Talevich et al. 2016) and
visualizedwithNexusCopyNumber (Biodiscovery). SeeSupplemental Table 3 for sequencing
coverage details.
FISH Testing
FISH testing was performed by the Pathology Department at Valley Children’s Hospital in
Madera, California according to standard protocols. Probes for detecting the EWSR1 fusion
were from Abbott Molecular.
Histopathology
Four micrometer sections of formalin-fixed paraffin-embedded tissue were stained with he-
matoxylin and eosin. Immunostaining and detection were performed on a Leica Bond III au-
tomated immunostainer using primary antibodies, clones, dilutions and sources,
respectively: synaptophysin (polyclonal; 1:100, Cell-Marque), SOX10 (EP268, 1:250 Cell-
Marque), CD99 (EPR3097Y, 1:100, Cell-Marque), H3K27Me3 (C36B11, 1:50, Cell
Signaling Technology). Synaptophysin was done to investigate the presence of neuroendo-
crine differentiation—SOX10 for nerve sheath/melanocytic differentiation and CD99 as a
sensitive, but not specific, stain for ES.
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ADDITIONAL INFORMATION
Data Deposition and Access
Raw sequencing data were not deposited but are available from the authors on reasonable
request. TheNF1 and EWSR1-ERG variants described in this studywere submitted to ClinVar
(http://www.ncbi.nlm.nih.gov/clinvar/) and can be found under accession numbers
SCV000993588–SCV000993590.
Ethics Statement
Verbal consent was obtained from themother of this patient to publish this article. The verbal
consent was obtained in Spanish by Dr. Alejandro Sweet-Cordero and witnessed by
Dr. Avanthi Shah, who are both fluent in Spanish and authors of this manuscript. The patient
is directly cared for by another author of this manuscript (Dr. Fernandez), who also obtained
consent from the mother verbally for sharing of this information. We have IRB consent
for registry of cases sequenced by our CLIA-certified assay (University of California, San
Francisco IRB 18-24582).
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